Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ruth Cholhan

Rheumatology Englewood Cliffs, NJ Medical Doctor

NPI 1447291653 CMS profile 831446

385 Sylvan Avenue Suite 26, Ruth C. Cholhanmd, Englewood Cliffs, NJ 07632

Open in the dashboard

General payments

$7,337

466 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ruth Cholhan of Englewood Cliffs, NJ is reported in the CMS Open Payments database as having received $7,337 across 466 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,478 78
2024 General $1,916 96
2023 General $769 52
2022 General $955 66
2021 General $742 49
2020 General $336 23
2019 General $1,142 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ruth Cholhan
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Ruth Cholhan were reported at $1,478. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Ruth Cholhan Rheumatology median Middle half National median
2019 $1,142 $744 $153–$2,687 $163
2020 $336 $462 $98–$2,027 $114
2021 $742 $531 $101–$2,153 $132
2022 $955 $627 $125–$2,303 $149
2023 $769 $741 $145–$2,524 $160
2024 $1,916 $830 $166–$2,660 $164
2025 $1,478 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,386 71 payments
  2. AbbVie, Inc. $1,074 71 payments
  3. Janssen Biotech, Inc. $729 55 payments
  4. UCB, Inc. $658 39 payments
  5. Pfizer Inc. $524 66 payments
  6. Novartis Pharmaceuticals Corporation $515 26 payments
  7. AstraZeneca Pharmaceuticals LP $362 25 payments
  8. Lilly USA, LLC $312 20 payments
  9. GlaxoSmithKline, LLC. $267 16 payments
  10. E.R. Squibb & Sons, L.L.C. $224 15 payments
  11. Other $1,287 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,177 464 payments
  2. Education $160 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $695 46 payments
  2. XELJANZ $524 66 payments
  3. Cimzia $483 30 payments
  4. EVENITY $421 21 payments
  5. TREMFYA $407 20 payments
  6. KRYSTEXXA $337 6 payments
  7. COSENTYX $331 16 payments
  8. SIMPONI ARIA $314 34 payments
  9. TALTZ $297 19 payments
  10. BENLYSTA $267 16 payments
  11. Other $3,712 230 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

918

Median for Rheumatology: 1,511

Drug cost

$943,045

Median for Rheumatology: $1,139,948

Branded share of claims

42.8%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 36 $264,559
Xeljanz Xr Tofacitinib Citrate Brand 37 $243,574
Orencia Clickject Abatacept Brand 29 $151,241
Humira(Cf) Pen Adalimumab Brand 18 $124,746
Taltz Autoinjector Ixekizumab Brand 18 $111,606
Prolia Denosumab Brand 11 $18,004
Methotrexate Methotrexate Sodium Brand 231 $7,781
Leflunomide Generic 131 $6,885
Hydroxychloroquine Sulfate Generic 117 $6,128
Cevimeline Hcl Generic 14 $5,264

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$537,098

Of which drugs: $456,545

Medicare patients

185

Average age 76

Services billed

76,705

140 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 45%
Diabetes 33%
Ischemic heart disease 23%
Chronic kidney disease 16%
Atrial fibrillation 15%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 20 64,402 $226,850
Injection, denosumab, 1 mg J0897 Office 28 2,220 $45,874
Injection, methylprednisolone acetate, 1 mg J1010 Office 16 1,030 $103
Infusion, normal saline solution, 250 cc J7050 Office 19 84 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $225
$225 — —
EVENITY
  • Amgen Inc. $166
$166 — —
RINVOQ
  • AbbVie, Inc. $156
$156 — —
KRYSTEXXA
  • Amgen Inc. $154
$154 — —
XELJANZ
  • PFIZER INC. $142
$142 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

466 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record